PharmaLive (press release) (subscription) Study: Abilify Maintena Reduces Psychiatric Hospitalization Rates. Study Shows Effects of Treatment with ABILIFY MAINTENA™ ( Aripiprazole ) on Psychiatric Hospitalization Rates for Patients with Schizophrenia... Read More ... and more »
SBWire (press release) Aripiprazole (marketed as Abilify), Asenapine Maleate (marketed as Saphris), Clozapine (marketed as Clozaril), Iloperidone (marketed as Fanapt), Lurasidone (marketed as Latuda), Olanzapine (marketed as Zyprexa), Olanzapine/ Fluoxetine (marketed as ... and more »
MarketWatch (press release) "Nancy's exceptional grasp of the opportunities and challenges entailed in product launches, commercial development and operational growth will add significant strategic perspective as candidates from our pipeline portfolio, namely aripiprazole ... and more »
Regina Leader-Post Only one of the drugs, aripiprazole , or Abilify, has been approved for use in children, and only then for schizophrenia in teens aged 15 to 17. At UBC, Panagiotopoulos's research has shown that children exposed to second-generation antipsychotics have ... and more »
7thSpace Interactive (press release) ... 24 weeks in patients suffering from schizophrenia treated with pomaglumetad methionil (LY2140023 monohydrate, the prodrug of metabotropic glutamate 2/3 receptor agonist, LY404039) or standard of care (SOC: olanzapine, risperidone, or aripiprazole ).
Seeking Alpha Our most advanced candidate, Aripiprazole Lauroxil formerly referred to as ALKS 9070 is our long-acting injectable pro-drug of Aripiprazole , currently enrolling patients in a large Phase III study. Our FDA filing timeline is driven by two major ...
MedPage Today SAN FRANCISCO -- Schizophrenia patients switching from regular daily antipsychotic medications to a long-acting form of aripiprazole (Abilify Maintena) had markedly fewer hospitalizations, a researcher said here. Hospitalization rates were slashed by ... and more »
